Centbutindole vs trifluoperazine: a double-blind controlled clinical study in acute schizophrenia.

Abstract	Twenty-nine acute schizophrenic patients were treated under double-blind conditions for six weeks with either centbutindole in a dose range of 3 mg/day to 4.5 mg/day or trifluoperazine in the dose range of 15 mg/day to 22.5 mg/day. Both drugs produced a significant improvement in initial psychopathology. No significant differences were demonstrated between the two treatment conditions.
Authors	D R Doongaji, R S Satoskar, A S Sheth, J S Apte, A B Desai, B R Shah
Journal	Journal of postgraduate medicine (J Postgrad Med) Vol. 35 Issue 1 Pg. 3-8 (Jan 1989) ISSN: 0022-3859 [Print] India
PMID	2685263 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Pyrazines Trifluoperazine centbutindole
Topics	Adult Clinical Trials as Topic Double-Blind Method Female Humans Male Pyrazines (adverse effects, pharmacology, therapeutic use) Random Allocation Schizophrenia (diagnosis, drug therapy) Trifluoperazine (adverse effects, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!